RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Bavarian Nordic A/S Stock

Bavarian Nordic A/S Stocks 2024

Bavarian Nordic A/S Stocks

76.71 M

Ticker

BAVA.CO

ISIN

DK0015998017

WKN

917165

In 2024, Bavarian Nordic A/S had 76.71 M outstanding stocks, a 0% change from the 76.71 M stocks in the previous year.

The Bavarian Nordic A/S Stocks history

YEARNUMBER OF STOCKS (undefined DKK)
2029e76.71
2028e76.71
2027e76.71
2026e76.71
2025e76.71
2024e76.71
202376.71
202270.42
202163.1
202054.05
201940.81
201840.77
201740.3
201638.34
201536.16
201426.36
201326.1
201226.1
201120.7
201015
200912
200812
200711.5
20069.6
20058.2
20047

Bavarian Nordic A/S shares outstanding

The number of shares was Bavarian Nordic A/S in 2023 — This indicates how many shares 76.711 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bavarian Nordic A/S earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bavarian Nordic A/S's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bavarian Nordic A/S’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bavarian Nordic A/S's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bavarian Nordic A/S Aktienanalyse

What does Bavarian Nordic A/S do?

Bavarian Nordic A/S is a biopharmaceutical company based in Denmark, specializing in the development and production of vaccines. The company was established in 1994 as a spin-off from the University of Copenhagen and has been listed on the Copenhagen stock exchange since 1998. The company's history began with an innovation developed by Professor Peter Andersen at the University of Copenhagen - the Viruslike Particles (VLP) technology. This technology serves as the basis for the production of vaccines against severe infectious diseases such as influenza, RSV, or HPV. Bavarian Nordic utilizes this technology to generate effective immune responses without using live pathogens. The company's business model is focused on two areas: the commercial vaccine sector and the biodefense products sector. The commercial sector includes the development and production of vaccines for cancer (such as prostate cancer or breast cancer) as well as infectious diseases like RSV. The biodefense products sector concentrates on protection against biological attacks, with the company manufacturing vaccines against bioweapons such as anthrax or smallpox for governmental institutions. Bavarian Nordic is divided into various business divisions. One of these is the commercial vaccines department, which develops and produces vaccines for the commercial market, particularly for cancer indications. The company also has a biodefense products department, which safeguards governmental institutions and organizations against bioterrorist attacks and other threats posed by biological weapons. This department focuses on the development and production of vaccines against smallpox, anthrax, and Ebola virus. Bavarian Nordic offers a wide range of products. The commercial vaccine Prostvac against prostate cancer is the company's flagship product. Other vaccines that have been developed or are still in development include vaccines against breast cancer, influenza, RSV, and lung cancer. The biodefense products encompass vaccines against smallpox, anthrax, and Ebola virus, as well as preclinical development programs for additional biological attacks. The company has also signed cooperation agreements with other companies to accelerate the research and development of new products. These include collaborations with Bristol Myers Squibb and Janssen Pharmaceutica for the development of cancer vaccines, as well as with the British Ministry of Defence for the development of vaccines against anthrax. Overall, Bavarian Nordic A/S caters to a broad range of interests and business sectors. The company focuses on the development and production of vaccines for both commercial and governmental institutions, aiming to enhance protection against biological threats and infectious diseases. Thanks to its innovative VLP technology, the company is a key player in the field of vaccine development and offers a wide range of products. Bavarian Nordic A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Bavarian Nordic A/S's Shares Outstanding

Bavarian Nordic A/S's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Bavarian Nordic A/S’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Bavarian Nordic A/S’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Bavarian Nordic A/S’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Bavarian Nordic A/S stock

How many stocks are there of Bavarian Nordic A/S?

The current number of stocks of Bavarian Nordic A/S is 76.71 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Bavarian Nordic A/S are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Bavarian Nordic A/S evolved in recent years?

The number of shares of Bavarian Nordic A/S has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Bavarian Nordic A/S as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Bavarian Nordic A/S?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Bavarian Nordic A/S pay?

Over the past 12 months, Bavarian Nordic A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bavarian Nordic A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Bavarian Nordic A/S?

The current dividend yield of Bavarian Nordic A/S is .

When does Bavarian Nordic A/S pay dividends?

Bavarian Nordic A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bavarian Nordic A/S?

Bavarian Nordic A/S paid dividends every year for the past 0 years.

What is the dividend of Bavarian Nordic A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bavarian Nordic A/S located?

Bavarian Nordic A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bavarian Nordic A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bavarian Nordic A/S from 7/28/2024 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 7/28/2024.

When did Bavarian Nordic A/S pay the last dividend?

The last dividend was paid out on 7/28/2024.

What was the dividend of Bavarian Nordic A/S in the year 2023?

In the year 2023, Bavarian Nordic A/S distributed 0 DKK as dividends.

In which currency does Bavarian Nordic A/S pay out the dividend?

The dividends of Bavarian Nordic A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Bavarian Nordic A/S stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Bavarian Nordic A/S

Our stock analysis for Bavarian Nordic A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bavarian Nordic A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.